ESCRS Homepage

July 2003
IN THIS ISSUE
Ocular symptoms often the first sign of CMV-R in HIV- infected patients

When measuring quality of vision - scatter matters

Symposium to highlight ‘The next generation of IOLs'


Anti-HIV Drugs Save Vision of AIDS Patients


HIV is a risk factor for corneal ulceration


HIV-infection implicated in ischaemic maculopathy


Unexpected visual sensations may alarm surgical patients undergoing peribulbar anaesthesia


OHTS study shows that risk factor profiling can aid in treatment decisions for ocular hypertensives


Hi- tech centres boost care for glaucoma patients


OCT reliable, accurate technique for corneal thickness measurement


French survey shows changing practice patterns


Pre-op pupillometry reduces post-op unhappiness


French ophthalmology at a turning point?


US cataract surgeons change with the times


US LASIK market static but outlook good


Prosperity around the corner?


Russian mobile ophthalmic surgery unit brings relief to dispersed elderly population


Industry Briefs


Virtual reality lab boosts hi-tech vision research


Patients forget about two-thirds of doctors' treatment instructions, says neuropsychologist


Outlook on industry: Spin-off brings the best of both worlds


Incidence of wavefront aberrations varies widely in healthy eyes


FEATURES
From The Editor

Reflections on Refractive Surgery

Bio-Ophthalmology. From foe to friend: using HIV to treat genetic eye disease


Regulatory Matters. LASIK malpractice lawsuits establish European beachhead


Journal Watch. Vision science highlights from the world's leading journals of medicine and science


Intraocular antiseptic doubles as medium for Seidel testing


In your good books

 


FROM THE EDITORS BY PAUL ROSEN FRCS, FRCOPHTH

 

Back in April my mother was diagnosed as having breast cancer. The UK government requires that patients with a malignancy are seen within two weeks of diagnosis and receive surgery in a similar period. So far very good. She required radiotherapy which should be done 6 weeks post-operatively. Not so good: she is told she will have to wait a further 4 months before this can be done. Why?

Not enough staff, not enough financial resources and it’s the same throughout the UK. The same week I receive an e-mail telling me that the government is spending in excess of 80m euro to reduce the waiting time for cataract surgery to three months. Initially, we would all welcome this type of investment, but the bulk of this money will not necessarily go to the Government health service, but to independent overseas providers.

Audits have shown that our threshold for cataract surgery has been reduced such that we are now operating on patients before they develop a significant visual disability. Of course this magnanimous initiative is an easy way for the government to meet their own targets and is not based on the wider clinical needs of the population: their distorted vision.

Part of the problem is that we have made it too easy for governments, who regard a cataract as an intraocular chalazion: there appears to be no understanding of the logistics in performing surgery and the numbers that are safely achievable. Leaming’s survey is, as always, fascinating.

That the majority of surgeons in America perform 50 or fewer phacoemulsification procedures per month correlates with throughput in Europe. There are, in fact, very few surgeons worldwide who can reliably perform high volume cataract surgery and this is corroborated by the articles from France, with the majority performing less than 500 surgeries per annum.

It is also noteworthy that 60% of surgeons in the US reuse phaco tips, a practice which is outlawed by EU law. The attitude of the French Government is interesting, employing "divide and rule" tactics by empowering optometrists, a group with whom we should be working in harmony. These surveys provide us with a degree of realism: our undistorted vision.